Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
The overall prevalence of H. Pylori in the developing countries is 50.8%, with the highest
one presented in Africa (79.1%). Hybrid therapy is supposed to be more effective as a
first-line regimen for Helicobacter pylori infection in Egypt than the Reverse hybrid and
non-bismuth Levofloxacin quadruple therapies. We are aiming here to compare the Hybrid,
Reverse hybrid, and Levofloxacin quadruple therapies as first-line therapy, trying to reach
the safest, cost-effective, and compliance-inducing regimen in Egypt. We will conduct a
randomized controlled (interventional) study at Zagazig University Hospital, internal
medicine department clinic, on 330 patients. 110 patients will be allocated to each regimen.